and DEVOTE met its primary goal of a cardiac safety profile that was no worse than Lantus. In 2015, the FDA finally approved Tresiba (insulin degludec) and Ryzodeg (insulin aspart and insulin ...

which is developing its own next-generation long-acting insulin, as well as a 2-in-1 combination of its existing long-acting Tresiba and GLP-1 analogue Victoza, to be called IDegLira. However ...